Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
Background Different types of tumors have varying susceptibility to immunotherapy and hence require different treatment strategies; these cover a spectrum ranging from ‘hot’ tumors or those with high mutational burden and immune infiltrates that are more amenable to targeting to ‘cold’ tumors that a...
Main Author: | Kellsye P Fabian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/2/e001691.full |
Similar Items
-
Senescence Inflames the Pancreatic Tumor Microenvironment
by: Giulia Petroni, et al.
Published: (2020-05-01) -
Hybrid Fc‐fused interleukin‐7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy
by: Ji‐Hae Kim, et al.
Published: (2020-01-01) -
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
by: Riyue Bao, et al.
Published: (2020-10-01) -
Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors
by: Jenny Bulgarelli, et al.
Published: (2019-10-01) -
Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors
by: Yukun Huang, et al.
Published: (2020-01-01)